McGrew Matthew sold $4.1M of DHR

McGrew Matthew (Executive Vice President) sold 17,385 shares of DANAHER CORP /DE/ (DHR) at $235.69 ($4.10M total) on 2026-11-09.

Original reporting
SEC EDGAR · McGrew Matthew
Published Nov 10, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DHR
Bearish
medium confidence
Mentioned
$DHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted by the market as a neutral to slightly negative signal.

02

Market read

A modest insider sale; likely limited price impact but worth monitoring for any follow‑on activity.

03

What to watch

Potential tax planning or pre‑planned liquidity needs unrelated to company outlook.

Relevance 6/10Novelty 6/10Timing: after-market today

Background

Form 4 filings are mandatory disclosures of insider transactions, providing transparency to investors.

Company-level read

Ticker impact

$DHRBearishMedium confidence
Context

Executive Vice President Matthew McGrew sold 17,385 shares for $4.1M, reducing his stake to 12,674 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

The sale size is modest relative to Danaher's market cap, but insider transactions often prompt short-term selling pressure.

Market effects

Minimal impact on the broader healthcare/tools sector.

U.S. market only; no regional ripple.

Low; Danaher is a global player but the insider sale is company‑specific.

Counterpoint

The sale could be a routine diversification and not indicative of future performance.

Key entities

  • Danaher Corp

    Global science and technology conglomerate (ticker DHR).

  • Matthew McGrew

    Executive Vice President of Danaher.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.